ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 235,55
0,35%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. RenovoRx Inc (RNXT)

  7. RenovoRx Inc (RNXT) Actualités

RNXT

RenovoRx (RNXT)

RenovoRx Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RNXT
DateHeureSourceTitreSymboleSociété
10/06/202414h30GlobeNewswire Inc.RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and PartnershipsNASDAQ:RNXTRenovoRx Inc
07/06/202422h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNXTRenovoRx Inc
30/05/202414h30Business WireRenovoRx CEO Issues Update Letter to ShareholdersNASDAQ:RNXTRenovoRx Inc
21/05/202415h00Business WirePublication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment DeliveryNASDAQ:RNXTRenovoRx Inc
14/05/202415h00Business WireRenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024NASDAQ:RNXTRenovoRx Inc
13/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RNXTRenovoRx Inc
10/05/202423h21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNXTRenovoRx Inc
10/05/202422h50Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RNXTRenovoRx Inc
02/05/202415h00Business WireRenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024NASDAQ:RNXTRenovoRx Inc
18/04/202414h30Business WireRenovoRx Regains Compliance with Nasdaq Stockholders’ Equity RequirementNASDAQ:RNXTRenovoRx Inc
16/04/202414h30Business WireRenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific MeetingNASDAQ:RNXTRenovoRx Inc
15/04/202414h00Business WireRenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026NASDAQ:RNXTRenovoRx Inc
08/04/202414h30Business WireRenovoRx Announces $11.1 Million at Market Private PlacementNASDAQ:RNXTRenovoRx Inc
05/04/202414h30Business WireRenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024NASDAQ:RNXTRenovoRx Inc
12/03/202414h00Business WireRenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024NASDAQ:RNXTRenovoRx Inc
08/03/202422h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNXTRenovoRx Inc
08/03/202422h26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RNXTRenovoRx Inc
08/03/202422h05Business WireRenovoRx Highlights Key Leadership PromotionsNASDAQ:RNXTRenovoRx Inc
09/02/202422h15Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:RNXTRenovoRx Inc
06/02/202414h30Business WireRenovoRx CEO Issues Letter to ShareholdersNASDAQ:RNXTRenovoRx Inc
29/01/202414h30Business WireRenovoRx Closes $6.1 Million Private PlacementNASDAQ:RNXTRenovoRx Inc
21/12/202314h30Business WireRenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct CancerNASDAQ:RNXTRenovoRx Inc
19/12/202314h30Business WireRenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific MeetingNASDAQ:RNXTRenovoRx Inc
13/12/202314h31Business WireRenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy PlatformNASDAQ:RNXTRenovoRx Inc
27/11/202319h23Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:RNXTRenovoRx Inc
17/11/202323h30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RNXTRenovoRx Inc
16/11/202314h35Business WireRenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.NASDAQ:RNXTRenovoRx Inc
14/11/202314h30Business WireRenovoRx Reports Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:RNXTRenovoRx Inc
02/10/202314h30Business WireRenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023NASDAQ:RNXTRenovoRx Inc
17/08/202314h30Business WireRenovoRx Reports Second Quarter 2023 Financial Results and Operational HighlightsNASDAQ:RNXTRenovoRx Inc
 Showing the most relevant articles for your search:NASDAQ:RNXT

Dernières Valeurs Consultées

NASDAQ
AMZN
Amazon.com
COIN
BTCUSD
Bitcoin
EU
PX1
CAC 40
NYSE
MRK
Merck
EU
AI
Air Liquide
NASDAQ
GOOGL
Alphabet
EU
BNP
BNP Paribas
EU
ML
Michelin
EU
ACA
Credit Agricole
EU
RI
Pernod Ricard
EU
GLE
Societe Generale
EU
BEL20
Bel 20
EU
RNO
Renault
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés